阿德福韦酯联合双歧三联活菌治疗乙肝肝硬化腹水的疗效评价(2)
 |
| 第1页 |
参见附件。
510310，China[Abstract] Objective To evaluate the therapeutic effect of adefovir dipivoxil associated with live combined bifidobacterium and lactobacillus in the treatment of pateints with type B posthepatitic cirrhosis and ascites. Methods Ninety—one patients with type B hepatitis liver cirrhosis and ascites were collected， who were accepted conventional treatment after admission including protecting liver， diureses and regularly transfusion albumin or plasma etc. All the patients were randomly 1divided into treatment group(46 cases received adefovir dipivoxil 10 mg once a day and live combined bifidobacterium and lactobacillus tablet 2.0 g three times a day treatment)， control A group (23 cases， received live combined bifidobacterium and lactobacillus tablet 2.0g three times a day treatment) and control B group (22 cases received conventional treatment only). Hepatic function and ascites were assessed after treatment for 3 months and 12 months respectively. Results The liver function improvement and ascites extinction were significantly better in treantent group than that in control A group and control B group， the difference had statistical significance(P < 0.05)；The ascites recur rate was 11.4% in treatment group， which compared with that in control A group(81.8%)and control B group (90.0%) had statistics difference (P < 0.05). Conclusion The therapy of adefovir dipivoxil associated with live combined bifidobacterium and lactobacillus on pateints with type B posthepatitic cirrhosis and ascites has a good effect， which is worth of learning.[Key words] Adefovir dipivoxil；Live combined bifidobacterium and lactobacillus；Hepatic cirrhosis and ascites
您现在查看是摘要介绍页，详见PDF附件(2013kb)。